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A B S T R A C T
Objective: To study the effects on quality of life in women operated for apical pelvic organ prolapse using
the Vaginal UpholdTM System.
Study design: In this prospective cohort study, women (n = 207) with symptomatic apical prolapse, with
or without cystocele, were operated using the UpholdTM Vaginal Support System. Follow-up for quality of
life was performed at 12 months after surgery, and assessed by the PFDI-20, and PFIQ-7, and sexual
function by the PISQ-12. We used odds ratios (ORs) with 95% conﬁdence intervals (CIs) for outcome
association analyses using logistic regression.
Results: At one-year follow-up majority of women experienced an overall postoperative improvement in
quality of life (p < 0.001). One year after surgery UpholdTM operation alone increased the risk for prolapse
related bother as compared to UpholdTM combined with anterior colporraphy (POP-IQ-7; OR 2.1; 95% CI
1.01–4.3). The frequency of dyspareunia decreased postoperatively (p = 0.004), however, after one-year,
overall sexual function deteriorated signiﬁcantly (p < 0.001). The worsening in sexual function scores
was mainly attributed to the partner related domain, whereas the behavioral-emotive and physical
domains showed no signiﬁcant changes.
Conclusion: Apical prolapse repair using UpholdTM improved quality of life among our patients but
worsened overall sexual function postoperatively.
ã 2016 Elsevier Ireland Ltd. All rights reserved.
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Although the restoration of vaginal topography often results in
improvements in pelvic organ prolapse symptoms the incongru-
ence between objective and subjective outcomes in pelvic organ
prolapse surgery is well established [1–3]. As a consequence, the
focus of pelvic organ prolapse surgery has pivoted towards patients
centered outcomes and quality of life measures, [4–6] rather than
simply measuring pelvic anatomy outcomes of surgery.
In women after pelvic organ prolapse surgery quality of life
measures may entail a variety of domains of which the effects on
sexual function has received perhaps the most attention [7].
Nonetheless, it remains unclear how, and to what extent, sexual* Corresponding author at: Helsinki University Hospital, Department of Obstet-
rics and Gynecology, BOX 140, 00029 HUS, Helsinki, Finland.
E-mail address: paivi.rahkola-soisalo@hus.ﬁ (P. Rahkola-Soisalo).
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0301-2115/ã 2016 Elsevier Ireland Ltd. All rights reserved.dysfunction relates to pelvic reconstructive surgery. Some studies
suggest that sexual dysfunction is a common sequela after mesh
augmented reconstructive surgery [8,9], others suggest that
surgery has no effect [10–12], or even improve sexual function
domains [13,14]. Ambiguous results have also been shown for
other quality of life domains in relation pelvic organ prolapse
surgery.
We have previously reported on the safety and efﬁcacy
outcomes and subjective relief of condition speciﬁc symptoms
after using the UpholdTM Vaginal Support System [15]. In the
present study we assessed quality of life and sexual function
outcomes following UpholdTM surgery in a prospective cohort of
women with apical prolapse and with or without concurrent
cystocele.
Table 1
Baseline characteristics and the operation information.
Age y, mean  SD (range) 66.3  9.2 (34–92)
Weight 70.1  9.4
BMI mean  SD (range) 25.3  4.6 (19.6–
35.3)
Parity median (range) 2 (0–5)
Multiparous (3 deliveries) N (%) 78 (38)
Menopause N (%) 183 (88)
Smokers N (%) 11 (5)
Somatic diseases N (%)
No diseases 68 (33)
Cardiovascular diseases 81 (39)
Thyroid dysfunction 21 (10)
Asthma 12 (6)
Diabetes 4 (2)
Fibromyalgia + rheumatism 6 (3)
Other 4 (2)
Previous surgeries N (%)
Hysterectomy 79 (38)
Subjects with previous pelvic ﬂoor surgery 88 (43)
Hysterectomy or incontinence + colporraphia anterior 39 (19)
Operating time min (mean  SD) 54.6  18.8
Bleeding ml, mean  SD (range) 78  122 (0–1000)
Hospital stay days median (range) 2 (0–7)
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We performed a multicenter, prospective, open label, single
cohort study throughout 24 clinics in Sweden, Denmark, Norway
and Finland. A total of 207 patients with primary or secondary
apical prolapse stage 2 (point C/D), with or without anterior
vaginal wall prolapse > or equal to 1 (point Ba >1), according to
POP-Q staging [16], underwent surgery using the UpholdTM Lite
Vaginal Support System (Boston Scientiﬁc). All patients underwent
a pre-trial standardized surgical procedure using the UpholdTM Lite
system and all gynecologic surgeons participating in the trial had
supervised hands-on operating room training before initiation of
the study. The surgical procedure has been described elsewhere
[17]. Brieﬂy a small incision was used, leaving approximately 2 cm
undisturbed at the vaginal apex. The Capio1 Suture Capturing
Device was used to connect the mesh to the sacrospinosus
ligament and suspending the apex. If decided by the operator,
anterior vaginal wall prolapse was corrected concomitantly by
traditional colporraphia anterior, but there was not any stage of
prolapse when this was mandatory. The peri- and postoperative
morbidity and complications associated with the procedure were
reported by Altman et al. [15]. Follow-up visits were performed at
two months and one year after surgery. Five women did not attend
any follow-up and thus, the ﬁnal cohort was 202 women.
There were no restrictions on body mass index, menopausal
status, or previous surgery. Other pelvic disorders for which
surgery was indicated (including stress incontinence, cervix
elongation and posterior prolapse), as well as, previous or current
pelvic organ cancer, severe rheumatic disease, insulin treated
diabetes mellitus, connective tissue disorder, and current systemic
steroid treatment were regarded as exclusion criteria’s.
Vaginal topography and quantiﬁcation of pelvic organ prolapse
was assessed at baseline, as well as, after two months and one year
postoperatively during a gynecological exam in the lithotomy
position using the POP-Q system [16]. Stage <2 of the apical
compartment was considered an optimal anatomical outcome
after surgery.
Quality of life outcomes were assessed using the Pelvic Floor
Distress Inventory 20 (PFDI-20), Pelvic Floor Impact Question-
naire- short form 7 (PFIQ-7), Pelvic Organ Prolapse/Urinary
Incontinence Sexual Questionnaire (PISQ-12) at baseline and
one year follow-up. The main results of PFDI-20 are reported
before [15], but these data were included here when analyzing the
possible risk factors for subjective operation failure. The PFIQ-7
provides a comprehensive condition speciﬁc assessment of the
effect of pelvic ﬂoor distress on quality of life during the last three
months. The questionnaire includes seven questions and three
scales: Urinary Impact Questionnaire (UIQ-7), Colorectal-Anal
Impact Questionnaire (CRAIQ-7), and Pelvic Organ Prolapse Impact
Questionnaire (POPIQ-7). The scale score is obtained by the mean
value of all the answered questions and multiplying them to obtain
scale score from 0 (least impact) to 100 (greatest impact). In the
summary higher points indicates more distress. The PISQ consists
of 12 questions, which measures the impact of pelvic organ
prolapse on the patient’s sexual life during the last six months. The
responses are graded on a 5-point Likert scale from “never” to
“always”. The questionnaire can be divided to three subscales,
behavior-emotional, physical, and partner related. Higher points
indicate better sexual satisfaction and the maximum score is 48.
Data on the quality of life questionnaires are presented as
means  SD. Comparison between baseline and one-year out-
comes were analyzed by the Wilcoxon –Matched-Paired-Signed-
Rank test. As possible risk factors for unsuccessful outcomes
(i.e. POP-Q stage 2 in point C or an adverse effects on quality of life
instruments) we evaluated a number of variables in a multivariate
logistic regression analysis including: previous hysterectomy,previous pelvic organ prolapse surgery, age >65 years, BMI 25,
multiparity (3 deliveries), chronic diseases (cardiovascular
diseases, asthma, thyroidea dysfunction, non-insulin treated
diabetes, ﬁbromyalgia, rheumatism), and concomitant anterior
vaginal wall repair. Results from the risk analysis are presented as
odds ratios (ORs) with 95% conﬁdence intervals (CIs). A
p-value < 0.05 was considered signiﬁcant for all analyses. All
statistics were performed with IBM SPSS Statistics, version 22.
The study was approved by the appropriate research ethics
committees in the participating countries and the study was
registered at www.clinicaltrials.gov (NCT01823055). The study
protocol was vetted by the mesh manufacturing company prior to
providing an investigator initiated study grant but the company
had no further inﬂuence over execution of the study, analyses and
interpretation of the data, or drafting the manuscript. Further-
more, the company provided funding for two investigator meet-
ings held before and after completion of the trial.
Results
Baseline characteristics of the patients included in the study are
presented in Table 1. In total 88% of the women were postmeno-
pausal (183) and 38% (79 women) had a history of previous
hysterectomy. Mean age at surgery was 66.3 (SD 9.2) years, mean
body mass index (BMI) was 25.3 (SD 4.6) and median parity was 2
(range 0–5).
The PFIQ-7 questionnaire was ﬁlled adequately by 197 women
at baseline, and after one year by 183 women. Of these women 179
ﬁlled the questionnaires adequately both at baseline and at one
year. One hundred-sixteen (64.8%) women had lower score points
one year postoperatively indicating an improved quality of life, 19
(10.6%) women reported no change, and 44 (24.6%) women
showed worsening in quality of life. Detailed outcome of PFIQ-7
questionnaire is presented in Table 2. Pelvic organ prolapse and
urinary symptoms caused equal distress before the operation. The
total score points showed an overall improved quality of life at one-
year follow-up (p < 0.001) (Table 2). Both pelvic organ prolapse and
urinary problems improved signiﬁcantly after one year (p < 0.001),
whereas in the colorectal-anal scale no statistically signiﬁcant
change was detected (Table 2).
Table 2
Pelvic ﬂoor impact quality questionnaire results.
Preop. N = 197 1 year N = 183 p
Pelvic organ prolapse impact 49.4  25 36.4  13.1 <0.001
Colorectal-anal impact 39.1  20.4 36.2  11.7 0.3
Urinary impact 49.7  23.3 40.1  13.1 <0.001
Total 138.5  59.8 105.1  42.5 <0.001
Means  SD.
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the PISQ-12 questionnaire adequately. Of these 94 women
answered completely for both questionnaires. In 62 (66.0%)
women total score points reduced postoperatively indicating
worsening in sexual function, 10 (10.6%) women reported
unchanged situation, and 22 (23.4%) women showed improved
sexual function. Overall sexual satisfaction was reduced (p < 0.001)
after one-year follow-up (Table 3). In the subscale analyses the
score points did not differ in the behavioral-emotive and physical
sections before and after surgery. There was, however, a speciﬁc
decrease in the partner related subscale postoperatively (Table 3).
With regard to postoperative dyspareunia in speciﬁc (PISQ-12,
question 5) a total of 98 women answered the question both pre
and postoperatively. Of these 58/98 women (59.2%) had some
dyspareunia preoperatively whereas 42 reported (42.9%) dyspar-
eunia postoperatively (p = 0.004). Fifty patients reported no
change, 32 patients improved, and in 16 patients dyspareunia
worsened. A worsening in dyspareunia was reported by 8.1% of all
studied women having an Uphold procedure vs. 8.3% among
women having Uphold with concomitant colporraphy (p = 0.9).
Similarly, 12.5% of women reported a complete resolution of
dyspareunia after an isolated Uphold procedure vs. 11.7% among
patients having Uphold with concomitant colporraphy (p = 0.6).
In Table 4 we present the results for the association between
possible predictors and a worsening of condition speciﬁc
symptoms, quality of life, sexual function and anatomical out-
comes. Chronic disease improved the odds of quality of life
improvement (OR 0.4, 95% CI; 0.2–0.9) whereas an age 65
increased the risk for de novo pelvic organ prolapse (OR 2.5, 95% CI;
1.01–6.2). There were no signiﬁcant associations between any ofTable 3
Pelvic Organ prolapse/Urinary Incontinence Sexual Questionnaire results.
Baseline N = 95 1 year N = 97 p
Behavioral emotive 6.9  3.5 6.8  3.3 0.7
Physical 4.7  3.0 4.2  2.6 0.07
Partner 3.6  2.9 1.6  2.5 <0.001
Summary Score 15.2  6.1 12.6  6.2 <0.001
Means  SD.
Table 4
Odd ratios OR for unsuccessful operation result after one year follow-up (POP-Q <2 ap
De novo prolapse Apical success 
OR 95% CI OR 95% CI
Previous hysterectomy 1.2 0.5–2.7 0.8 0.2–3.3
Previous pelvic ﬂoor surgery 0.8 0.4–1.7 1.1 0.3–4.6
BMI 25 1.3 0.6–2.8 0.8 0.2–3.6
Multiparous 1.1 0.5–2.4 0.6 0.2–3.3
Age 65 2.5
0.047*
1.01–6.2 0.2 0.2–1.9
Chronic disease 0.8 0.4–1.9 0.7 0.1–4.0
Isolated UpholdTM operation 0.5 0.2–1.1 0.5 0.1–2.0
* p-values for signiﬁcant OR.the co-variates and sexual dysfunction or anatomical outcomes
(Table 4).
In the subscale analyses of both the PFDI-20 (UDI-6) and the
PIFQ-7 (UIQ-7) there was increased odds for improved urinary
distress in women with BMI 25 (OR 0.3, 95% CI; 0.1–0.7, and OR
0.5, 95% CI; 0.2–0.9, respectively). Among women with a history of
previous pelvic ﬂoor surgery and among women with an isolated
UpholdTM (no concurrent anterior colporraphy) there was an
increased risk that the operation worsened urinary distress (UIQ-7;
OR 2.2, 95% CI; 1.1–4.4 and OR 2.3, 95% CI; 1.1–4.9, respectively).
Having an isolated UpholdTM operation also increased the risk for
prolapse related bother one year after surgery (POP-IQ-7; OR 2.1,
95% CI; 1.01–4.3).
Comment
The total scores indicated that the UpholdTM operation
signiﬁcantly improved quality of life as reﬂected by lower scores
postoperatively for the PFIQ-7. At baseline there was almost as
much distress from urinary symptoms as from pelvic organ
prolapse, and both these symptoms of pelvic ﬂoor dysfunction
improved signiﬁcantly after the operation. These results are
comparable with previous studies on the use of mesh in pelvic
organ prolapse repair [3,14,18–20].
Despite the improvement in quality of life, PISQ-12 scores
showed an overall worsening in sexual function 1-year postoper-
atively. The deterioration was mainly attributed to negative effects
in the partner related domain whereas the behavioral-emotive and
physical domains showed no signiﬁcant changes. To some extent
this concurs with a previous cohort study showing that transvagi-
nal mesh is associated with deteriorating partner related sexual
function [8]. Although partner related sexual dysfunction after
prolapse surgery is a recurrent ﬁnding in studies on pelvic organ
prolapse surgery the mechanisms for this ﬁnding are poorly
understood. It is possible that the PISQ-questionnaire as a tool to
describe sexual function, although responsive to change after
surgery [21], does not provide a comprehensive and detailed
enough evaluation of the complexity involved in sexual function
after reconstructive surgery. In-depth studies on sexual dysfunc-
tion related to pelvic organ prolapse surgery are scarce. In a mixed
quantitative and qualitative study [22], the investigators found
that partner avoidance of sexual activity was greater in women
after prolapse surgery as compared to incontinence surgery. In
contrast, another study [23] showed that sexual function in male
partners of women after pelvic organ prolapse surgery was
unchanged or even improved. Moreover, it is possible that this
worsening is attributable to prolapse surgery itself – regardless of
using mesh or not [24]. However, we may conclude that partner
related dysfunction after mesh augmented or native tissue
prolapse repair may be an important cause of postoperative
sexual dysfunction and deserves further attention.ical compartment, PFDI-20, PFIQ-7, PISQ-12).
PFDI-20 PFIQ-7 PISQ-12
 OR 95% CI OR 95% CI OR 95% CI
 0.8 0.2–3.0 0.5 0.2–1.1 1.1 0.4–3.1
 2.4 0.8–7.1 1.0 0.5–2.3 1.0 0.4–2.8
 0.5 0.1–1.6 0.8 0.4–1.6 0.7 0.3–1.9
 0.7 0.2–2.5 2.1 1.0–4.2 1.4 0.5–3.8
 3.6 0.7–18.1 1.1 0.5–2.4 0.9 0.3–2.5
 3.3 0.7–16.3 0.4
0.02*
0.2–0.9 0.8 0.3–2.3
 1.5 0.4–5.1 1.5 0.7–3.1 1.0 0.3–2.9
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has received the greatest attention relating to urogynecological
surgery. Again ﬁndings from previous studies are conﬂicting and
some studies show an increased risk for dyspareunia after surgery
whereas others detected no change [8–14]. We found that the
number of women with dyspareunia decreased postoperatively,
even if almost half of the women who answered the question (42/
98) had some dyspareunia one year after the operation. Most of
these women presented dyspareunia seldom or sometimes, and
only four women had pain often or always. However, it is notable
that only 48.5% of women answered the question and thus, it is
possible that the true rate of dyspareunia was higher. There was no
difference in either worsening or improvement of dyspareunia
when comparing women having an isolated UpholdTM procedure
compared to those having it in combination with anterior
colporraphy. These numbers are comparable with previous study
where 8% of women had de novo dyspareunia after Uphold
operation [25]. It is possible that the decreased biomaterial load
and smaller surface of the mesh when performing an apical
suspension procedure such as UpholdTM decreases the risk for
postoperative dyspareunia when compared to the large scale
transvaginal meshes used to cover defects of the vaginal walls
[8,9]. Thus, our data suggest that performing an anterior
colporraphy at the time of an Uphold procedure does not add to
the risk of postoperative dyspareunia, whereas overall conclusions
on sexual function and dyspareunia are restricted.
We evaluated risk factors in subjective and objective outcomes,
as well as, for de novo prolapse. Surprisingly, the only signiﬁcant
variable positively associated with an overall improvement in
quality of life (PFIQ-7) was co-existent chronic diseases. It is
possible that women afﬂicted by multiple chronic diseases
experience after surgery improvements in prolapse symptoms
more clearly than otherwise healthy women with perhaps greater
expectations on daily function. Age 65 years was a risk factor for
de novo prolapse which likely reﬂects the association between
prolapse and age [26]. In addition, it is possible that among elderly
women, with overall poorer tissue quality, the effectiveness of
mesh surgery in the afﬂicted compartment may promote de novo
prolapse in other compartments [27].
Women having an isolated UpholdTM operation reported less
improvement in both lower urinary tract and pelvic organ prolapse
related distress as compared to women having a concomitant
cystocele operation. This is in line with our ﬁnding that women
without any preoperative cystocele reported at baseline less
urinary distress (PFDI-20; p = 0.004). Concomitant cystocele repair
may increase the support of the bladder neck providing additional
improvement of lower urinary tract symptoms and especially
stress urinary incontinence. It is known that isolated traditional
cystocele correction relives preoperative stress urinary inconti-
nence in 27% of the women [28]. Furthermore, the concomitant
cystocele repair probably provide better overall support to the
anterior compartment than UpholdTM alone resulting in improved
symptom relief. In the subscale analyses of both the PFDI-20 and
PFIQ-7, a higher degree of satisfaction with regard to lower urinary
tract symptoms were found in obese women (BMI 25). Since
obese women had more distress in the urinary sections
preoperatively (PFDI-20; p < 0.001, PFIQ-7; p = 0.06), they likely
beneﬁted more from the operation than normal weight women.
The apparent limitation of our study is that approximately half
of our patients chose not to reply to the PISQ-12. In addition, our
non-randomized study design include potential bias such as
doctor-patient relationship, care seeking behavior, and patient/
surgeon preferences. As a strength of our study can be regarded the
prospective, multicenter and multinational study setting.
In conclusion, use of the Vaginal UpholdTM Support System for
apical prolapse repair improve quality of life and no speciﬁc riskfactors for subjective operation failure could be identiﬁed.
However, there was an overall worsening in sexual function
postoperatively.
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